Compare TNET & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | TSHA |
|---|---|---|
| Founded | 1988 | 2019 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2000 | 2020 |
| Metric | TNET | TSHA |
|---|---|---|
| Price | $42.84 | $5.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $65.80 | $11.63 |
| AVG Volume (30 Days) | 336.0K | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $5,010,000,000.00 | $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $1,152.42 |
| P/E Ratio | $21.30 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $33.67 | $2.25 |
| 52 Week High | $86.78 | $7.30 |
| Indicator | TNET | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 38.37 |
| Support Level | $34.47 | $5.37 |
| Resistance Level | $46.38 | $6.02 |
| Average True Range (ATR) | 2.28 | 0.43 |
| MACD | -0.19 | -0.19 |
| Stochastic Oscillator | 59.76 | 2.85 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.